India, Sept. 16 -- Dr Reddy's Laboratories on Tuesday announced the launch of Tegoprazan (50 mg) under the brand name PCAB in India to treat acid-related gastrointestinal conditions.
Tegoprazan, a next-generation potassium-competitive acid blocker, is indicated for managing acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive GERD (NERD), and Gastric Ulcers.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....